MCRB Seres Therapeutics

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 13, 2024 at 8:30 a.m. ET to discuss third quarter 2024 financial results and provide business updates.

To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 5051385. To join the live webcast, please visit the “Investors and News” section of the Seres website at .

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). SER-155 and our other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via single-strain cultivation, rather than from the donor-sourced production process used for VOWST. The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. For more information, please visit .

Investor and Media Contact:  

Carlo Tanzi, Ph.D.

Kendall Investor Relations



EN
06/11/2024

Underlying

MCRBSeres Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Seres Therapeutics

 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics Announces Appointment of Richard N. Kender as Execu...

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026 SER-155 i...

11h / 30m 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Provides Program and Corporate Updates and Prioritizes Emerging ...

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause further investment, while efforts to seek funding for the study remain ongoing Company’s runway extension actions, including reducing the workforce by approximately 30%, are expected to extend its cash runway through Q3 2026 Seres will focus on advancing deve...

February 12, 2026 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics Announces Publications in Nature Medicine and Journ...

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx® platform provides high-resolution functional biological understanding of live biotherapeutics and supports the advancement of Seres’ portfolio, including Phase 2-ready lead candidate SER-155 CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq...

January 6, 2026 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics to Participate in Piper Sandler Healthcare Conferen...

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 a.m. ET. A live webcast of the chat will be accessible through the “Events and Presentations” tab on the “Investors and News” section of the Company’s website at and will be available for replay following the event. About Seres Thera...

November 24, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Pr...

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results anticipated within 12 months of study initiation Ongoing investigator-sponsored study in immune checkpoint...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch